ARTICLE | Clinical News
SR Pharma starts Phase II with SRP299
June 19, 2001 7:00 AM UTC
SR Pharma (LSE:SPA) began a U.K. dose-ranging Phase II trial of its SRP299 heat killed Mycobacterium vaccae suspension in 120 patients with asthma. The trial is funded by Sakai Chemical ( Sakai City, ...